한글목차

아트라센탄은 강력하고 선택적인 엔도세린 A(ETA) 수용체 길항제이며, IgA 신증(IgAN) 및 기타 단백질 요성 사구체 질환과 같은 여러 만성 신장 질환에서 단백질 소변을 감소시킵니다. 신장 기능을 유지하는 직접적인 항 염증 작용 이나 항섬유화 작용을 가짐으로써 이익을 가져올 가능성이 있습니다. 했습니다.

현재, 이 회사는 추가의 단백질 요성 사구체 질환을 대상으로 한 2상(NCT04573920) AFFINITY 시험에서 동제를 평가했습니다. 닌 비율(UPCR)이 0.5-1.0g/g 미만인 IgAN 환자, 둥근 국소 분절 사구체 경화증(FSGS)(FSGS), 알포트 증후군, 당뇨병성 신장병(DKD)의 4가지 코호트가 있습니다.

이 보고서는 주요 7개국의 아트라센탄 시장에 대해 조사했으며,, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 알포트 증후군에 있어서의 아트라센탄의 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 아트라센탄 시장 평가

• 알포트 증후군에서 아트라센탄 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"Atrasentan Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Atrasentan for Alport syndrome in the seven major markets. A detailed picture of the Atrasentan for Alport syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Atrasentan for Alport syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Atrasentan market forecast analysis for Alport syndrome in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Alport syndrome.

Drug Summary:

Atrasentan is a potent and selective endothelin A (ETA) receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases such as IgA nephropathy (IgAN) and other proteinuric glomerular diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. The company in-licensed atrasentan from AbbVie in December 2019, which previously developed atrasentan for diabetic kidney disease (DKD).

Currently, the company is evaluating the drug in Phase II (NCT04573920) AFFINITY study in additional proteinuric glomerular diseases. The basket trial has four cohorts consisting of patients with IgAN with urine protein to creatinine ratio (UPCR) of 0.5 to less than 1.0 g/g, focal segmental glomerulosclerosis (FSGS), Alport syndrome, and diabetic kidney disease (DKD).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Atrasentan description, mechanism of action, dosage and administration, research and development activities in Alport syndrome.
• Elaborated details on Atrasentan regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Atrasentan research and development activities in Alport syndrome across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Atrasentan.
• The report contains forecasted sales of Atrasentan for Alport syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alport syndrome.
• The report also features the SWOT analysis with analyst views for Atrasentan in Alport syndrome.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Atrasentan Analytical Perspective by DelveInsight

• In-depth Atrasentan Market Assessment

This report provides a detailed market assessment of Atrasentan for Alport syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Atrasentan Clinical Assessment

The report provides the clinical trials information of Atrasentan for Alport syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Alport syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Atrasentan dominance.
• Other emerging products for Alport syndrome are expected to give tough market competition to Atrasentan and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Atrasentan in Alport syndrome.
• Our in-depth analysis of the forecasted sales data of Atrasentan from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Atrasentan in Alport syndrome.

Key Questions:

• What is the product type, route of administration and mechanism of action of Atrasentan?
• What is the clinical trial status of the study related to Atrasentan in Alport syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Atrasentan development?
• What are the key designations that have been granted to Atrasentan for Alport syndrome?
• What is the forecasted market scenario of Atrasentan for Alport syndrome?
• What are the forecasted sales of Atrasentan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Atrasentan for Alport syndrome?
• Which are the late-stage emerging therapies under development for the treatment of Alport syndrome?

Table of Contents

1. Report Introduction

2. Atrasentan Overview in Alport syndrome

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Atrasentan Market Assessment

• 5.1. Market Outlook of Atrasentan in Alport syndrome
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Atrasentan in the 7MM for Alport syndrome
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Atrasentan in the United States for Alport syndrome
  • 5.3.2. Market Size of Atrasentan in Germany for Alport syndrome
  • 5.3.3. Market Size of Atrasentan in France for Alport syndrome
  • 5.3.4. Market Size of Atrasentan in Italy for Alport syndrome
  • 5.3.5. Market Size of Atrasentan in Spain for Alport syndrome
  • 5.3.6. Market Size of Atrasentan in the United Kingdom for Alport syndrome
  • 5.3.7. Market Size of Atrasentan in Japan for Alport syndrome

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options